

Cite this: *RSC Adv.*, 2017, 7, 21625Received 4th March 2017
Accepted 6th April 2017

DOI: 10.1039/c7ra02657a

rsc.li/rsc-advances

A facile strategy for the synthesis of a NaREF₄-gold nanocomposite as a dual-modal bioimaging agent†

Bin Shen,^{id} Yilin Gao, Qingyun Liu, Shengming Cheng, Wei Feng^{id}*
and Fuyou Li^{id}*

In this article, a facile strategy is developed to synthesize a nanocomposite containing both a rare earth doped upconversion nanoparticle (RE-UCNP) and gold nanoparticles (GNPs). Such a nanocomposite can serve as a dual-modal imaging agent for upconversion luminescence (UCL) imaging and photoacoustic tomography (PAT). High spatial resolution, 3-dimensional imaging of blood vessels could be achieved with the RE-UCNP/GNPs@SiO₂ nanocomposite by PAT, while UCL imaging offers a high-speed, low-interference and 2-dimensional imaging mode.

1 Introduction

Non-invasive imaging has become a useful tool for bioimaging, detection and medical diagnosis.^{1–8} To date, lots of non-invasive imaging techniques, including fluorescence imaging,⁹ magnetic resonance imaging (MRI),¹⁰ X-ray computed tomography (CT),¹¹ positron emission tomography (PET),^{4,11,12} single-photon emission computed tomography (SPECT)¹² and photoacoustic tomography (PAT),^{13,14} have been developed. As every single technique has its own limits (e.g., spatial resolution, imaging depth and scanning speed), developing multimodal non-invasive imaging is of great importance to combine the merits of individual imaging techniques.

Among the optical imaging agents, rare-earth doped upconversion nanoparticles (RE-UCNPs) are unique imaging agents because of their upconversion emission. Upconversion luminescence (UCL) of the RE-UCNPs features large anti-stokes shift which can effectively avoid the auto-fluorescence interferences of bio-samples. Under the excitation of a near infrared continuous-wave laser source, RE-UCNPs can emit light ranging from ultraviolet to near-infrared. Benefiting from the versatile rare earth elements, RE-UCNPs can be easily functionalized with suitable rare earth ions for multimodal imaging. For instance, the Gd³⁺-doped RE-UCNPs were demonstrated to be potential MRI contrast agents and the radioisotope ¹⁵³Sm-doped RE-UCNPs were used as gamma-emitting tracers in SPECT.^{15–17} Due to the high atomic number of the lanthanide ions embedded, RE-UCNPs can absorb X-rays efficiently and be directly used as CT contrast agents.

PAT is an emerging non-radiative and versatile technique for bioimaging ranging from organelles to organs.¹⁸ This emerging technology overcomes the high degree of scattering of optical photons in biological tissue by making use of the photoacoustic effect. The combination of PAT and UCL may be endowed with high scanning speed and high spatial resolution with no radiation risk. It is hard to realize PAT with RE-UCNP alone since RE-UCNPs do not have significant absorption band from visible to near infrared. Gold nanoparticles (GNPs) have a strong and tuneable extinction band ranging from visible to near infrared area and are widely used in photothermal treatment and photoacoustic imaging.^{19–21} Thus a nanocomposite containing RE-UCNP and GNPs may be an ideal dual-modal agent for PAT and UCL imaging. Herein we developed a strategy for the synthesis of RE-UCNP/GNPs@SiO₂ nanocomposite. A layer of porous silica was initially coated on the RE-UCNPs (NaREF₄). With the functional groups inside the silica pores, GNPs nucleated in the pores through *in situ* reduction of HAuCl₄. The silica layer can bind the two kinds of nanoparticles tightly and also provide an inert and biocompatible surface.

2 Results and discussion

2.1 Preparation of RE-UCNP/GNPs@SiO₂ nanocomposite

The synthesis route of RE-UCNP/GNPs@SiO₂ nanocomposite is depicted in Fig. 1. Tm³⁺ and Yb³⁺ co-doped NaYF₄ nanoparticles were synthesized *via* a modified method reported by Zhang *et al.*²² Then the as-prepared RE-UCNPs were coated with silica through a modified water-in-oil microemulsion method. Two different kinds of silica layers were coated on the nanoparticles successively. The inner layer of silica was alkylamino-functionalized organic silica, co-condensed from tetraethyl orthosilicate (TEOS) and *N*-[3-(trimethoxysilyl)propyl]ethylenediamine (TSD). The outer layer was hydrolysed from TEOS to form a compact, hydrophilic and bio-compatible layer. As

Department of Chemistry, The State Key Laboratory of Molecular Engineering of Polymers, Institute of Biomedicine Science, Collaborative Innovation Center of Chemistry for Energy Materials, Fudan University Shanghai, 200433, P. R. China.
E-mail: fyli@fudan.edu.cn; fengweifd@fudan.edu.cn

† Electronic supplementary information (ESI) available: Additional characterizations. See DOI: 10.1039/c7ra02657a




Fig. 1 Schematic representation showing the synthesis strategy of the RE-UCNP/GNPs@SiO₂ nanocomposite.




Fig. 2 TEM images of (a) RE-UCNP; (b) RE-UCNP@NH₂-SiO₂@SiO₂; (c) RE-UCNP@porous-NH₂-SiO₂@SiO₂; (d and e) RE-UCNP/GNPs@SiO₂. Scale bar: (a–d) 100 nm, (e) 10 nm.

shown in Fig. 2, transmission electron microscopy (TEM) images show that the as-prepared nanoparticles (NaYF₄:Yb,Tm) are in uniform shape and have the average diameter of 24 nm.

Upon successive silica-coating, UCNP@NH₂-SiO₂@SiO₂ nanocomposite was synthesized and the silica layer can be easily distinguished from the core by TEM. The as-prepared nanocomposites are *ca.* 50 nm in diameter (Fig. 2b). The nanocomposites were then etched with HF solution (10% wt.) with precise control. The inner layer, co-condensed from TSD and TEOS, is a loose organic-silica framework and can be selectively etched by HF.^{23,24}

Through precise control, the inner layer of the silica was partially etched and tiny pores appeared within the outer-shell of silica after the HF treatment (Fig. 2c). The inner layer of the silica can be completely removed to form a yolk-shell structure if additional HF is added (Fig. S1a†). Excess HF would lead to the etch of the entire silica shell (Fig. S1b†). The alkylamino groups in the pores can serve as *in situ* reducing agents to form gold nanoparticles. The porous nanocomposites (UCNP@porous-NH₂-SiO₂@SiO₂) were mixed with a proper amount of HAuCl₄ and heated at 80 °C. As shown in Fig. 2d and e, GNPs can be clearly recognized within the silica layer in our nanocomposite by TEM. UV-Vis absorption spectra of the final composite (RE-UCNP/GNPs@SiO₂) shows a wide absorption band from 500 nm to 850 nm, which is attributed to the




Fig. 3 UV-Vis absorption spectra (black) and UCL spectra (blue) of RE-UCNP/GNPs@SiO₂ nanocomposite.

absorption of aggregated-state gold nanoparticles in the nanocomposites (Fig. 3).^{25–27} Under the excitation of a 980 nm cw-laser source, intense UCL band at 800 nm (³H₄ → ³H₆) emitted by the nanocomposite could also be observed (Fig. 3). Dynamic light scattering (DLS) was performed to track the hydrated diameter and dispersity of our nanomaterial in each step (Fig. S2†). No significant change was observed in size and dispersity after GNPs-loading. The large cavity of yolk-shell structure, etched by additional HF, can also be utilized to grow and carry gold nanoparticles (Fig. S3†). EDXA and XRD were used to confirm the components of the as-synthesized nanocomposites (Fig. S4 and S5†). Compared to the UCNP/GNPs assembled by coordination interaction,²⁸ the RE-UCNP/GNPs@SiO₂ composite in the present work is supposed to be more stable and robust in tough conditions, since the GNPs were embedded within the silica layer.^{29–32}

2.2 Photoacoustic tomography

To examine the viability of the as-prepared nanocomposites as PAT contrast agents, we initially performed *in vitro* PAT in an Eppendorf tube. The nanocomposites were dispersed in deionized water and tested. Another tube containing deionized water was tested as control.

As shown in Fig. 4a, the photoacoustic signal can be clearly distinguished from the background while no signal was detected in the control test. Then we performed the *in vivo* PAT with an anesthetized Kunming mouse. Fig. 4b and c are selected slices of the three-dimensional reconstructed data of the thoracic cavity and abdomen with/without material. Before injection, only some main vessels could be vaguely recognized, as the hemoglobins are endogenous contrast agents of PAT. The same mouse was then injected with the nanocomposites intravenously. With the help of the nanocomposites, the photoacoustic signal was significantly enhanced. A clear view of the main vessels was obtained and branch vessels emerged. In the abdomen part, the injected one also had obvious improvements. The superficial epigastric arteries/veins lying on the liver were clearly imaged. Two lobes of the liver can be distinguished by the dark border in the middle. The 3D reconstruction data






Fig. 4 Selected scan slices of photoacoustic tomography of an anesthetized mouse. (a) *In vitro* test with RE-UCNP/GNPs@SiO₂ (top) and water (bottom); *in vivo* imaging of (b) the thoracic cavity and (c) abdominal cavity. All the photoacoustic data were collected under the excitation of a 680 nm pulse light source.

were collected and presented in ESI Movie 1.† In summary, RE-UCNP/GNPs@SiO₂ nanocomposites significantly enhanced the signal of *in vivo* PAT.

With the help of the such material, we obtained a stereoscopic view of the fine structure of liver, some major vessels as well as superficial vessels.

2.3 UCL imaging

To demonstrate the capability of the nanocomposite as a probe for UCL imaging, *in vivo* UCL imaging was carried out with the as-prepared nanocomposite. The nanocomposites were injected into a Kunming mouse by hypodermic injection. Under the excitation of an annular continuous-wave 980 nm laser source (30 mW cm⁻²), the UCL conversion signals at 800 ± 12 nm were collected. As shown in Fig. 5, UCL image with ultra-low auto-fluorescence interferences and high signal-to-noise ratio (SNR)




Fig. 5 *In vivo* UCL imaging with RE-UCNP/GNPs@SiO₂. (a) Bright field image; (b) UCL image with ROI areas. Signals were collected by band-pass filter at 800 ± 12 nm, excited with 980 nm laser source (30 mW cm⁻²); (c) merged image of bright field image and the UCL signals.

was obtained. SNR here is defined as the ratio of the average value of the signal area (μ_{sig}) to the standard deviation of the background (σ_{bg}):

$$\text{SNR} = \frac{\mu_{\text{sig}}}{\sigma_{\text{bg}}}$$

The SNR in this work is determined to be 150. The favorable performance of the nanocomposite can be attribute to the anti-stokes luminescence feature of UCL as well as the wavelength of the emission light that falls within the NIR window for bio-imaging (650–900 nm).³³

2.4 Cytotoxicity

We also measured the *in vitro* cytotoxicity of our nanocomposite towards KB cells with methylthiazolyltetrazolium (MTT) assay. The KB cells were incubated with the RE-UCNP/GNPs@SiO₂ of different concentrations ranging from 50 mg mL⁻¹ to 1200 mg mL⁻¹ for 24 h. 6 replicate groups were performed for each concentration. As shown in Fig. S6,† MTT assay indicated that the nanocomposites have no significant cytotoxicity within 1200 mg mL⁻¹ (24 h). The results can be mainly attribute to the favourable bio-compatible of the silica surface of the as-prepared nanocomposite.

3 Materials and instruments

3.1 Materials

All starting materials were obtained from commercial supplies. Rare earth oxides Y₂O₃ (99.999%), Yb₂O₃ (99.999%), Tm₂O₃ (99.999%), Gd₂O₃ (99.999%) were purchased from Shanghai Yue-long New Materials Co. Ltd. LnCl₃ were prepared as reported in the literature.³⁴ Octadecene (ODE) (>90%), oleic acid (OA) (>90%), Igepal CO-520, and N-[3-(trimethoxysilyl)propyl] ethylenediamine (TSD) were purchased from Sigma-Aldrich. All chemical reagents of analytical grade were used directly without further purification. Kunming mice (4 weeks) were purchased from the Second Military Medical University and were housed under standard environmental conditions. All animal experiments were performed in compliance with the guidelines of National Institute for Food and Drug Control, China, and were approved by the Institutional Animal Care and Use Committee, School of Pharmacy, Fudan University.

3.2 Characterization

The size and morphology of RE-UCNPs were characterized at 200 kV on a FEI Tec-nai G² 20 TWIN TEM. The upconversion luminescence emission spectra were recorded in a modified Edinburgh LFS-920 instrument. The excitation source was an external 9 W adjustable 980 nm semiconductor laser (Beijing Hi-Tech Optoelectronic Co., China) with an optic fiber accessory. Powder X-ray diffraction measurements were performed on a XD-2 diffractometer at a scanning rate of 8° min⁻¹ in the 2θ range from 5° to 90° (Cu Kα radiation, λ = 1.54056 Å). Photoacoustic tomography was performed by a Nexus 128



photoacoustic tomography system (acquiring wavelength 680 nm, water temperature: 37.9 °C, pulses: 30, laser energy: 1.93 mJ).

3.3 Synthesis of RE-UCNP

RECl₃ (1 mmol, Y : Yb : Gd : Er = 63 : 20 : 15 : 2) was dispersed in ODE (11.8 g) and OA (7.4 g). The mixture was stirred and heated to 120 °C for 30 min in a 100 mL flask to form an optical transparent solution. Then the solution was cooled down to room temperature. NaOH (0.100 g, 2.5 mmol) and NH₄F (0.148 g, 4 mmol) in methanol (10 mL) were added to the flask dropwisely. The solution was heated to 90 °C, repeatedly degassed and purged with nitrogen for three times. After that the solution was heated to 300 °C and kept for 1 h. Finally the solution was cooled to room temperature. The nanoparticles were collected by centrifugation (21 036 RCF/10 min) and washed with cyclohexane/ethanol (1 : 3) for three times. The as-prepared nanoparticles were dispersed in cyclohexane (10 mL). The Gd³⁺ ions in this work were used to obtain nanoparticles with suitable diameters for silica coating. The particle size can be tuned to 11 nm in diameter when the Gd³⁺ content was 30 mol% (Fig. S7†).

3.4 Synthesis of RE-UCNP@NH₂-SiO₂@SiO₂

The as-prepared RE-UCNPs solution (0.04 mL), Igepal CO-520 (0.5 g) was dispersed in cyclohexane (10 mL). The solution was stirred and treated with ultrasonic for 30 min. Then ammonia (0.1 mL, aq.) was added into the solution and the solution immediately turned muddy. The slurry was vigorous stirred until a transparent solution was formed. After that TEOS/TSD (18.25/1.75 μL) was added to the solution. TEOS (10 μL) was added 24 h later and the solution was kept for another 24 h. The nanocomposites were then precipitated by adding 5 mL acetone to the solution and collected by centrifugation (21 036 RCF/10 min). The nanocomposites were washed twice with ethanol/water (1 : 1) and dispersed in 10 mL water.

3.5 Synthesis of RE-UCNP/GNPs@SiO₂

To etch the inner layer of the silica, 10 μL HF (10 wt%) was added to the nanocomposites solution (10 mL) carefully and stirred for 1 h. Then the nanocomposites were collected by centrifugation, washed with water/ethanol (1 : 1). After that the nanocomposites were dispersed in 10 mL water and heated with 30 mg HAuCl₄ at 80 °C for 3 h. The final product was washed with water for 3 times and finally dispersed in 10 mL water. To get the yolk shell nanostructured nanocomposite, 20 μL HF was used instead.

3.6 In vitro cytotoxicity

in vitro cytotoxicity was measured by methyl thiazolyl tetrazolium (MTT) assays on the KB cells. Cells were seeded in a 96-well culture plate at ca. 5×10^4 per well and cultured at 37 °C and 5% CO₂ for 24 h. The cells were subsequently incubated with different concentrations of RE-UCNP/GNPs@SiO₂ (50, 100, 200, 400, 600, 800, 1000, 1200 μg mL⁻¹) for 24 h. After that, MTT (10

μL, 3 mg mL⁻¹) was added to each well and the plate was incubated for an additional 4 h at 37 °C. After the addition of DMSO (100 μL per well) for 10 min, the optical density OD570 value (Abs. value) of each well, with the background subtraction at 690 nm, was measured by a Tecan Infinite M200 monochromator-based multifunction microplate reader. Cell viability (%) = (average Abs. value of treated group)/(average Abs. value of control) × 100%.

3.7 In vitro PA imaging

UCNP/GNPs@SiO₂ (1 mg mL⁻¹, aq.) and deionized water (blank control) were added to Eppendorf tubes (200 μL) at the constant volume, respectively. PA imaging and tomography were captured at 680 nm using the Nexus 128.

3.8 In vivo UCL imaging and PA imaging

Before imaging, the mice were anesthetized with intraperitoneal injection of 100 μL chloral hydrate (10 wt%). For UCL imaging, a small-animal imaging system designed by our group is used.³⁵ The system includes a set of circular 980 nm laser sources and an Andor DU897 EMCCD as the detector. The UCL data was processed with the Kodak Molecular Imaging Software. For PA imaging, the mice were imaged immediately after injection (100 μL, 1 mg μL⁻¹ UCNP@NH₂-SiO₂@SiO₂). During the PA imaging, the corresponding region (abdominal or thoracic) were put in a special-shaped transparent container and immersed by water. The PAT data was simultaneously collected and reconstructed by the Nexus 128 software.

4 Conclusions

We have developed a simple strategy to synthesize silica coated RE-UCNP/GNPs@SiO₂ nanocomposites. This strategy provides us a feasible way to build a multifunctional nanocomposite based on individual functional nanomaterials. The as-synthesized nanocomposite in the work can be utilized as a dual-modal imaging agent for UCL imaging and PAT, possessing the merits of both UCL and PAT, including ultra-low background noises, real-time imaging, as well as high spatial resolution. In addition, the robust silica shell also improves the bio-compatibility of the nanocomposite.

Acknowledgements

The authors sincerely thank Pro. Zhang Xianzhong, Mr Guo Zhide and Mr Peng Qiaoli from Xianmen University for the support in PAT characterization. This study was financially supported by NSFC (21231004), Shanghai Sci. Tech. Comm. (15QA1400700), and MOST of China (2013CB733703 and 2015CB931800).

Notes and references

- 1 Y. Liu, Q. Su, M. Chen, Y. Dong, Y. Shi, W. Feng, Z. Y. Wu and F. Li, *Adv. Mater.*, 2016, **28**, 6625–6630.



- 2 N. M. Idris, M. K. Gnanasammandhan, J. Zhang, P. C. Ho, R. Mahendran and Y. Zhang, *Nat. Med.*, 2012, **18**, 1580–1585.
- 3 X. Wang, Y. Pang, G. Ku, X. Xie, G. Stoica and L. V. Wang, *Nat. Biotechnol.*, 2003, **21**, 803–806.
- 4 S. S. Gambhir, *Nat. Rev. Cancer*, 2002, **2**, 683–693.
- 5 E. B. Dickerson, E. C. Dreaden, X. Huang, I. H. El-Sayed, H. Chu, S. Pushpanketh, J. F. McDonald and M. A. El-Sayed, *Cancer Lett.*, 2008, **269**, 57–66.
- 6 G. Tian, L. Duan, X. Zhang, W. Yin, L. Yan, L. Zhou, X. Liu, X. Zheng, J. Li, Z. Gu and Y. Zhao, *Chem.-Asian J.*, 2014, **9**, 1655–1662.
- 7 W. Yin, L. Zhao, L. Zhou, Z. Gu, X. Liu, G. Tian, S. Jin, L. Yan, W. Ren, G. Xing and Y. Zhao, *Chem.-Eur. J.*, 2012, **18**, 9239–9245.
- 8 W. Yin, L. Zhou, Z. Gu, G. Tian, S. Jin, L. Yan, X. Liu, G. Xing, W. Ren, F. Liu, Z. Pan and Y. Zhao, *J. Mater. Chem.*, 2012, **22**, 6974–6981.
- 9 L. Cao, X. Wang, M. J. Meziani, F. Lu, H. Wang, P. G. Luo, Y. Lin, B. A. Harruff, L. M. Veca, D. Murray, S.-Y. Xie and Y.-P. Sun, *J. Am. Chem. Soc.*, 2007, **129**, 11318–11319.
- 10 P. Caravan, J. J. Ellison, T. J. McMurry and R. B. Lauffer, *Chem. Rev.*, 1999, **99**, 2293–2352.
- 11 T. Beyer, D. W. Townsend, T. Brun, P. E. Kinahan, M. Charron, R. Roddy, J. Jerin, J. Young, L. Byars and R. Nutt, *J. Nucl. Med.*, 2000, **41**, 1369–1379.
- 12 C. E. Clarke and M. Guttman, *Lancet*, 2002, **360**, 1767–1769.
- 13 Y. Wang, J. F. Wong, X. W. Teng, X. Z. Lin and H. Yang, *Nano Lett.*, 2003, **3**, 1555–1559.
- 14 H. F. Zhang, K. Maslov, G. Stoica and L. V. Wang, *Nat. Biotechnol.*, 2006, **24**, 848–851.
- 15 C. H. Dong, A. Korinek, B. Blasiak, B. Tomanek and F. van Veggel, *Chem. Mater.*, 2012, **24**, 1297–1305.
- 16 J. Zhou, M. Yu, Y. Sun, X. Zhang, X. Zhu, Z. Wu, D. Wu and F. Li, *Biomaterials*, 2011, **32**, 1148–1156.
- 17 Y. Yang, Y. Sun, T. Cao, J. Peng, Y. Liu, Y. Wu, W. Feng, Y. Zhang and F. Li, *Biomaterials*, 2013, **34**, 774–783.
- 18 L. V. Wang and S. Hu, *Science*, 2012, **335**, 1458–1462.
- 19 C. Kim, E. C. Cho, J. Chen, K. H. Song, L. Au, C. Favazza, Q. Zhang, C. M. Cobley, F. Gao, Y. Xia and L. V. Wang, *ACS Nano*, 2010, **4**, 4559–4564.
- 20 J. Chen, C. Glaus, R. Laforest, Q. Zhang, M. Yang, M. Gidding, M. J. Welch and Y. Xia, *Small*, 2010, **6**, 811–817.
- 21 S. Wang, K. J. Chen, T. H. Wu, H. Wang, W. Y. Lin, M. Ohashi, P. Y. Chiou and H. R. Tseng, *Angew. Chem., Int. Ed.*, 2010, **49**, 3777–3781.
- 22 Z. Li and Y. Zhang, *Nanotechnology*, 2008, **19**, 345606.
- 23 F. Gao, L. Li, T. Liu, N. Hao, H. Liu, L. Tan, H. Li, X. Huang, B. Peng, C. Yan, L. Yang, X. Wu, D. Chen and F. Tang, *Nanoscale*, 2012, **4**, 3365–3372.
- 24 L. Yao, B. Shen, C. Cao, W. Feng and F. Li, *RSC Adv.*, 2014, **4**, 20252–20255.
- 25 G. Wang and W. Sun, *J. Phys. Chem. B*, 2006, **110**, 20901–20905.
- 26 T. Atay, J.-H. Song and A. V. Nurmikko, *Nano Lett.*, 2004, **4**, 1627–1631.
- 27 I. Blakey, Z. Merican and K. J. Thurecht, *Langmuir*, 2013, **29**, 8266–8274.
- 28 Z. Li, L. Wang, Z. Wang, X. Liu and Y. Xiong, *J. Phys. Chem. C*, 2011, **115**, 3291–3296.
- 29 Q. J. He and J. L. Shi, *J. Mater. Chem.*, 2011, **21**, 5845–5855.
- 30 Y. S. Chen, W. Frey, S. Kim, K. Homan, P. Kruizinga, K. Sokolov and S. Emelianov, *Opt. Express*, 2010, **18**, 8867–8878.
- 31 G. P. Luke, A. Bashyam, K. A. Homan, S. Makhija, Y. S. Chen and S. Y. Emelianov, *Nanotechnology*, 2013, **24**, 455101.
- 32 Y. S. Chen, W. Frey, S. Kim, P. Kruizinga, K. Homan and S. Emelianov, *Nano Lett.*, 2011, **11**, 348–354.
- 33 R. Weissleder, *Nat. Biotechnol.*, 2001, **19**, 316–317.
- 34 Q. Liu, W. Feng, T. Yang, T. Yi and F. Li, *Nat. Protoc.*, 2013, **8**, 2033–2044.
- 35 L. Xiong, Z. Chen, Q. Tian, T. Cao, C. Xu and F. Li, *Anal. Chem.*, 2009, **81**, 8687–8694.

